Core Viewpoint - Unicycive Therapeutics, Inc. is implementing a 1-for-10 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective June 18, 2025, with trading on a split-adjusted basis starting June 20, 2025 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will combine every ten shares into one, reducing the number of issued shares from approximately 126,409,281 to about 12,640,929 [4]. - Stockholders will not receive fractional shares; instead, fractional interests will be rounded up to the next whole share [3]. - The reverse stock split will not affect stockholders' percentage ownership or voting power, except for minor changes due to fractional shares [3]. Group 2: Compliance and Adjustments - The reverse stock split aims to increase the bid price of the common stock to meet the $1.00 minimum bid price requirement for continued listing on Nasdaq [2]. - Proportionate adjustments will be made to the exercise prices and number of shares underlying stock options, warrants, and preferred stock as a result of the reverse stock split [5]. Group 3: Company Overview - Unicycive Therapeutics is focused on developing therapies for kidney diseases, with its lead investigational treatment, oxylanthanum carbonate, under FDA review for treating hyperphosphatemia in chronic kidney disease patients on dialysis [8]. - The second investigational treatment, UNI-494, is aimed at conditions related to acute kidney injury and has received orphan drug designation from the FDA [9].

KULR Technology (KULR -21.53%) stock is getting hit with huge selling action in Monday's trading. The company's share price was down 21.3% as of 3 p.m. ET, despite the S&P 500 (^GSPC 0.82%) being up 0.9% at the same point in the day's trading.KULR is seeing a big valuation pullback today following news that the company will carry out a reverse stock split. The new structure for the stock won't do anything to alter the fundamentals of the business, but investors are dumping shares ahead of the 8-for-1 revers ...

CINCINNATI, Ohio, June 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology, today reported that on June 11, 2025, the Company received a decision from the Nasdaq Hearings Panel granting the Company’s request for continued listing on The Nasdaq Stock Market, subject to the Company demonstrating compliance with the Na ...

Company Overview - O'Reilly Automotive has seen a remarkable stock performance, climbing 509% over the past decade and outperforming the S&P 500 index [3] - Since its IPO in April 1993, O'Reilly's stock has skyrocketed 56,350%, indicating strong business fundamentals and shareholder value [9] Stock Split Details - On March 13, O'Reilly's board approved a 15-for-1 stock split, which was implemented on June 10, reducing the share price from approximately $1,350 to $90 [6] - The stock split increased the number of outstanding shares by a factor of 15, making shares more accessible to investors [5][6] Business Model and Demand Stability - O'Reilly operates 6,416 stores, primarily selling aftermarket auto parts, which are in stable demand regardless of economic conditions [10] - The necessity of maintaining working automobiles supports consistent demand, as consumers tend to either drive more in good times or maintain existing vehicles during recessions [11] Financial Performance - O'Reilly generated $2 billion in free cash flow in 2024 and reported $455 million in Q1, with a history of using this cash for share buybacks [12] - The diluted outstanding share count has been reduced by 24% over the last five years, enhancing earnings per share [12] Valuation Considerations - O'Reilly's stock trades at a price-to-earnings ratio of 33.3, which is 38% higher than its trailing-10-year average, suggesting that the stock may be overvalued [13] - A recommendation is made for investors to consider waiting for a pullback before investing, although a dollar-cost averaging strategy could be viable for those bullish on the stock [13]

A reverse stock split consolidates the number of existing shares of corporate stock into fewer—and proportionally more valuable—shares. https://t.co/MSmqms8udw ...

HOUSTON, June 13, 2025 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a Bitcoin First Company and global leader in sustainable energy management, announced today that it will effect a 1-for-8 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on June 23, 2025. KULR’s common stock will continue to trade on the NYSE-American Market under the symbol “KULR” and under a new CUSIP numb ...

SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Compan ...

Core Viewpoint - Fastenal Company is a leading wholesale distributor of industrial and construction supplies, playing a critical role in the economy and demonstrating strong stock performance, nearly doubling investors' money over the past five years [2][12]. Group 1: Stock Performance and Market Position - Fastenal's stock split at the end of May aimed to enhance share accessibility and liquidity, attracting a broader base of investors, particularly retail investors [2][3]. - Following the stock split, Fastenal's stock price gained about 5% as it adjusted to find a new equilibrium [3]. - The company has a current stock price of $42.86, with a 12-month price target of $40.40, indicating a potential downside of 5.74% [13]. Group 2: Operational Strength and Growth Strategy - Fastenal's operational excellence is driven by its direct sales model and extensive distribution network, including the "Onsite" location model, which integrates deeply with customer operations [4][5]. - The company plans to add between 375 and 400 new Onsite locations in 2025, expanding its existing base of over 1,950 [6]. - Fastenal's product portfolio is diversifying, with "Safety and Other Industrial Products" seeing a 3.5% year-over-year increase in daily sales, outpacing traditional fasteners [7]. Group 3: Financial Health and Shareholder Commitment - Fastenal reported Q1 2025 net sales of $1.96 billion, a 3.4% increase year-over-year, with May 2025 daily sales showing a 2.5% rise [7]. - The company maintains a conservative capital structure with a debt-to-equity ratio of 0.03 and strong liquidity ratios, indicating a solid capacity to meet short-term obligations [8]. - Fastenal has a 26-year track record of increasing dividends, with an annual dividend of $0.88 per share, reflecting financial stability and disciplined capital management [10][11]. Group 4: Future Outlook - Fastenal's strong fundamentals, including operational efficiencies and disciplined capital allocation, support its potential for sustained growth [14]. - The company plans to invest between $180 million and $200 million in capital expenditures for 2025, primarily for expanding Onsite locations and deploying FAST Solutions [11].

BOSTON, June 13, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will implement a 1-for-20 reverse stock split of its issued and outstanding shares of common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual ...

Core Viewpoint - FibroGen, Inc. will implement a 1-for-25 reverse stock split to increase the per-share market price and regain compliance with Nasdaq listing requirements [2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will be effective at 5:00 p.m. Eastern Time on June 16, 2025, with trading on a split-adjusted basis starting June 17, 2025 [1]. - The number of issued and outstanding shares will decrease from approximately 101.1 million to about 4.0 million shares [3]. - Stockholders will receive cash payments for any fractional shares instead of receiving fractional shares [3]. Group 2: Approval and Purpose - The reverse stock split was approved by stockholders at the 2025 Annual Meeting held on June 4, 2025 [2]. - The primary goal of the reverse stock split is to increase the market price of FibroGen's common stock to meet Nasdaq's minimum bid price requirement [2]. Group 3: Company Overview - FibroGen is a biopharmaceutical company focused on developing novel therapies for cancer and anemia [5]. - Roxadustat is approved in multiple regions for treating anemia in chronic kidney disease patients [5]. - The company is also developing FG-3246, an antibody-drug conjugate for metastatic castration-resistant prostate cancer [5].